Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials

被引:79
作者
Barbui, Corrado [1 ]
Furukawa, Toshiaki A. [2 ]
Cipriani, Andrea [1 ]
机构
[1] Univ Verona, World Hlth Org,Dept Med & Publ Hlth, Collaborating Ctr Res & Training Mental Hlth, Sect Psychiat & Clin Psychol, I-37134 Verona, Italy
[2] Nagoya City Univ, Grad Sch Med Sci, Dept Psychiat & Cognit Behav Med, Mizuho Ku, Nagoya, Aichi, Japan
关键词
D O I
10.1503/cmaj.070693
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Concern has been raised about the efficacy of antidepressant therapy for major depression in adults. We undertook a systematic review of published and unpublished clinical trial data to determine the effectiveness and acceptability of paroxetine. Methods: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register, the Cochrane Central Register of Controlled Trials, the Glaxo-SmithKline Clinical Trial Register, MEDLINE and EM BASE up to December 2006. Published and unpublished randomized trials comparing paroxetine with placebo in adults with major depression were eligible for inclusion. We selected the proportion of patients who left a study early for any reason as the primary outcome measure because it represents a hard measure of treatment effectiveness and acceptability. Results: We included in our review 29 published and 11 unpublished clinical trials, with a total of 3704 patients who received paroxetine and 2687 who received with placebo. There was no difference between paroxetine and placebo in terms of the proportion of patients who left the study early for any reason (random effect relative risk [RR] 0.99, 99% confidence interval [CI] 0.88 - 1.11). Paroxetine was more effective than placebo, with fewer patients who did not experience improvement in symptoms of at least 50% (random effect RR 0.83, 99% CI 0.77 - 0.90). Significantly more patients in the paroxetine group than in the placebo group left their respective studies because of side effects (random effect RR 1.77, 95% CI 1.44 - 2.18) or experienced suicidal tendencies (odds ratio 2.55, 95% CI 1.17 - 5.54). Interpretation: Among adults with moderate to severe major depression in the clinical trials we reviewed, paroxetine was not superior to placebo in terms of overall treatment effectiveness and acceptability. These results were not biased by selective inclusion of published studies.
引用
收藏
页码:296 / 305
页数:10
相关论文
共 31 条
[1]   Statistics notes - Detecting skewness from summary information [J].
Altman, DG ;
Bland, JM .
BRITISH MEDICAL JOURNAL, 1996, 313 (7066) :1200-1200
[2]   Even more suicide attempts in clinical trials with paroxetine randomised against placebo [J].
Aursnes, Ivar ;
Tvete, Ingunn Fride ;
Gaasemyr, Jorund ;
Natvig, Bent .
BMC PSYCHIATRY, 2006, 6 (1)
[3]   Suicide attempts in clinical trials with paroxetine randomised against placebo [J].
Aursnes, Ivar ;
Tvete, Ingunn Fride ;
Gaasemyr, Jorund ;
Natvig, Bent .
BMC MEDICINE, 2005, 3 (1)
[4]   Evidence-based psychopharmacology: an agenda for the future [J].
Barbui, C. ;
Cipriani, A. .
EVIDENCE-BASED MENTAL HEALTH, 2007, 10 (01) :4-6
[5]   Publication bias in systematic reviews [J].
Barbui, Corrado ;
Cipriani, Andrea .
ARCHIVES OF GENERAL PSYCHIATRY, 2007, 64 (07) :868-868
[6]  
Bauer Michael, 2002, World J Biol Psychiatry, V3, P69, DOI 10.3109/15622970209150605
[7]   Fluoxetine versus other types of pharmacotherapy for depression [J].
Cipriani, A. ;
Brambilla, P. ;
Furukawa, T. A. ;
Geddes, J. ;
Gregis, M. ;
Hotopf, M. ;
Malvini, L. ;
Barbui, C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (04)
[8]   Suicide, depression, and antidepressants - Patients and clinicians need to balance benefits and harms [J].
Cipriani, A ;
Barbui, C ;
Geddes, JR .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7488) :373-374
[9]  
Clarke M J, 1997, J Eval Clin Pract, V3, P207, DOI 10.1046/j.1365-2753.1997.00005.x
[10]  
FDA/CDER, 2006, FDA BRIEF DOC DEC 13, P1